New technique reduces side-effects, improves delivery of chemotherapy nanodrugs

November 28, 2017 by Jocelyn Duffy, Carnegie Mellon University
Administering a combination of Abraxane and Intralipid results in less of toxicity of the chemotherapy drug in the kidney (bottom row) than administering Abraxane alone (top row). Credit: Carnegie Mellon University

Carnegie Mellon University researchers have developed a new method for delivering chemotherapy nanodrugs that increases the drugs' bioavailability and reduces side-effects.

Their study, published online in Scientific Reports, shows that administering an FDA-approved nutrition source prior to chemotherapy can reduce the amount of the that settle in the , liver and kidneys.

Nanodrugs, drugs attached to tiny biocompatible particles, show great promise in treatment of a number of diseases, including cancer. Delivery of these drugs, however, is not very efficient—only about 0.7 percent of chemotherapy nanodrugs reach their target tumor cells. The remainder are absorbed by other cells, including those in the liver, spleen and kidneys. When the drugs build up in these organs, they cause toxicity and side-effects that negatively impact a patient's quality of life.

Chien Ho, professor of biological sciences at Carnegie Mellon University, and his colleagues have developed a novel way to improve delivery of chemotherapy nanodrugs by using Intralipid, an FDA-approved nutrition source to temporarily blunt the reticuloendothelial system—a network of cells and tissues found throughout the body, including in the blood, lymph nodes, spleen and liver, that play an important role in the immune system.

Intralipid reduces the toxicity and improves the bioavailability and biodistribution of anti-cancer nanodrugs. Credit: Carnegie Mellon University

Ho and colleagues tested their technique in a rat model of cancer using three FDA-approved chemotherapy nanodrugs, Abraxane, Marqibo and Onivyde, and one experimental platinum-based anti-cancer nanodrug. In the study, they administered Intralipid one hour before giving the animal a chemotherapy nanodrug. They found that their method reduced the amount of the drug that was found in the liver, spleen and kidneys and reduced the drugs' toxic side-effects. They also found that more of the drug was available to attack tumor cells. Additionally, the Intralipid treatment had no harmful impact on tumor growth or drug efficacy.

The researchers believe that their drug delivery methodology can be applied to a variety of nanodrugs without any modifications to the drugs.

"This methodology could have a major impact in the delivery of nanodrugs not only for patients undergoing for cancer treatment but also to those being treated with nanodrugs for other conditions," said Ho.

Explore further: Targeting cancer cells with an implantable drug delivery system

More information: Li Liu et al. A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid, Scientific Reports (2017). DOI: 10.1038/s41598-017-16293-6

Related Stories

Targeting cancer cells with an implantable drug delivery system

April 20, 2017
An article published in Experimental Biology and Medicine (Volume 242, Issue 7, March, 2017) describes a new drug delivery system for the treatment of cancer. The study, led by Dr. Horst A. von Recum from the Department of ...

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism

July 6, 2017
(Medical Xpress)—A team of researchers working at the Albert Einstein College of Medicine in the U.S. has found evidence that suggests administering chemotherapy to breast cancer patients prior to surgery can put them at ...

New nanotechnology application for difficult-to-treat cancers

May 10, 2017
A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. ...

Recommended for you

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

Higher body fat linked to lower breast cancer risk in younger women

June 21, 2018
While obesity has been shown to increase breast cancer risk in postmenopausal women, a large-scale study co-led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher found the opposite is true ...

New treatment helps avoid deafness in child chemotherapy patients

June 21, 2018
An international trial has found that a medicine commonly used to treat poisoning is effective in reducing deafness in children receiving chemotherapy for cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.